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Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem
cell transplantation (alloHSCT) have a poor prognosis, and alternative therapies are needed for this patient popula-
tion. Blinatumomab, a bispeciﬁc T cell engager immunotherapy, was evaluated in an open-label, single-arm, phase II
study of adults with R/R Philadelphia chromosome-negative B cell precursor ALL and resulted in a rate of complete
remission (CR) or CR with partial hematologic recovery of peripheral blood counts (CRh) of 43% within 2 treatment
cycles. We conducted an exploratory analysis to determine the efﬁcacy and safety of blinatumomab in 64 patients
who had relapsed following alloHSCT before enrollment in the phase II study. Forty-ﬁve percent of the patients (29
of 64) achieved a CR/CRh within the ﬁrst 2 cycles of treatment, 22 of whom had a minimal residual disease (MRD)
response (including 19 with a complete MRD response). After 1 year and 3 years of follow-up, the median relapse-
free survival was 7.4 months for patients who achieved CR/CRh in the ﬁrst 2 cycles, and the median overall survival
was 8.5 months; overall survival rate (Kaplan-Meier estimate) was 36% at 1 year and 18% at 3 years. Grade 3 and 4
adverse events were reported in 20 patients (31%) and 28 patients (44%), respectively, with grade 3 and 4 neurologic
events in 8 and 2 patients, respectively, and grade 3 cytokine release syndrome in 2 patients. Eight patients had fatal
adverse events, including 5 due to infections. Seven patients had grade  3 graft-versus-host disease during the
study, none of which resulted in the discontinuation of blinatumomab or hospitalization. Our data suggest that bli-
natumomab is an effective salvage therapy in this patient population.
© 2019 American Society for Blood and Marrow Transplantation. This is an open access article under the CC BY-NC-
ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Key Words:
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The outcomes of patients with relapsed/refractory (R/R) acute
lymphoblastic leukemia (ALL) following allogeneic hematopoietic
stem cell transplantation (alloHSCT) are poor. A retrospective
analysis of adults with ALL who relapsed after ﬁrst alloHSCT andphocyte infusion with or without previous chemotherapy, radia-
tion therapy, cytoreductive chemotherapy, mild chemotherapy,
or palliative care, showed 1- and 2-year overall survival rates of
17% and 10%, respectively [1]. Overall survival rates from a simi-
lar analysis were 16% at 2 years and 8% at 5 years [2]. Two studies
that focused on outcomes of second alloHSCT found overall sur-
vival rates of 23% at 1 year [3] and 11% and 35% at 3 years [3,4].
Thus, there is a need for more effective salvage therapies for
patients with ALL who relapse after alloHSCT.
CD19 is expressed in almost all (> 90%) tested B lineage ALL
cells [5,6] and is a target for immunotherapy in ALL. Blinatu-
momab is a bispeciﬁc T cell engager (BiTE) immunotherapy
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simultaneously binds CD3+ cytotoxic T cells and CD19+ B cells
and redirects T cells to lyse malignant and normal B cells [7].
In a phase II study of 189 adults with R/R Philadelphia chro-
mosome (Ph)-negative B cell precursor ALL, treatment with
single-agent blinatumomab resulted in a rate of complete
remission (CR) or CR with partial hematologic recovery of
peripheral blood counts (CRh) of 43% within the ﬁrst 2 cycles
of treatment [9]. The median relapse-free survival was 5.9
months, and median overall survival was 6.1 months [9].
In the present exploratory analysis, we evaluated the efﬁ-
cacy and safety of blinatumomab in the 64 patients who had
relapsed following alloHSCT before enrollment in the phase II
blinatumomab study.METHODS
Study Design and Patients
Details of the design of the phase II study and study participants have
been published previously [9]. In brief, this open-label, single-arm, phase II
study was conducted in Europe and the United States. For the current analy-
sis, eligible patients were age 18 years with R/R Ph-negative B cell precursor
ALL who had relapsed following alloHSCT before enrollment in the study;
alloHSCT must have been performed at least 3 months before the start of
treatment. Additional eligibility criteria included 10% bone marrow blasts
with or without measurable extramedullary disease, Eastern Cooperative
Oncology Group performance status of 2, no active acute (grade II-IV) or
active chronic graft-versus-host disease (GVHD) or systemic treatment for
GVHD within 2 weeks before treatment start, and no history or presence of
clinically relevant central nervous system (CNS) pathology. This study is reg-
istered at ClinicalTrials.gov (NCT 01466179).
Patients received up to 5 cycles of blinatumomab with an end-of-study
visit 30 days after the last treatment cycle and efﬁcacy follow-up visits at 3, 6,
9, 12, 18, and 24 months after the start of treatment. Blinatumomab was
administered by continuous i.v. infusion at 9 mg/day for the ﬁrst 7 days of the
cycle 1, 28 mg/day from day 8 through the end of cycle 1, and 28 mg/day in
the subsequent cycles. A cycle consisted of continuous i.v. infusion of blinatu-
momab over 4 weeks, followed by a 2-week treatment-free interval. Blinatu-
momab treatment was interrupted if a patient experienced a grade 3
CNS-related adverse events or other clinically relevant grade 3 or 4 adverse
events and was restarted when the adverse event had resolved to grade 1 or
baseline. Blinatumomab was discontinued if treatment was interrupted for
more than 2 weeks due to an adverse event, a grade 4 CNS event, or at least 2
seizures.
Patients who achieved CR or CRh within the ﬁrst 2 cycles of treatment
could receive up to 3 additional cycles of consolidation treatment and could
also undergo alloHSCT. Patients with hematologic relapse during the follow-
up period (at least 3 months after the completion of treatment) could receive
up to 3 additional cycles of treatment (9 mg/day for the ﬁrst 7 days) for a max-
imum of 8 cycles.Outcomes of Patients with Previous AlloHSCT
Study endpoints included CR/CRh rate within the ﬁrst 2 cycles of treat-
ment with blinatumomab, alloHSCT after CR/CRh, minimal residual disease
(MRD) response (prespeciﬁed exploratory endpoint), incidence of adverse
events, relapse-free survival, and overall survival.
CR was deﬁned as bone marrow blasts 5% with no evidence of disease
and full recovery of peripheral blood counts (platelet count >100,000/mL and
absolute neutrophil count >1,000/mL). CRh was deﬁned as bone marrow
blasts 5% with no evidence of disease and partial recovery of peripheral
blood counts (platelet count >50,000/mL and absolute neutrophil count
>500/mL).
MRD response was deﬁned as MRD <10¡4 leukemic cells as measured by
polymerase chain reaction (PCR) at a central laboratory. Complete MRD
response, a subset of MRD response, was achieved if no PCR ampliﬁcation of
individual rearrangements of immunoglobulin genes or T cell receptor genes
was detected. Assay requirements were sensitivity of at least 10¡4 and quan-
titative measurement range of at least 10-4.Determination of T Cell Subsets at Study Baseline
Samples of lymphocyte subsets were obtained at screening from all
patients to investigate any effect of previous transplantation on the number
of T cells at study baseline. Flow cytometry was used to determine the num-
bers of CD4+ and CD8+ T cells, including CD4+ naïve T cells, central memory T
cells (TCM cells), and effector memory T cells (TEM cells). and CD8+ naïve T
cells, TCM cells, TEM cells, and effector memory RA T cells (TEMRA cells).Statistical Analysis
Patients who had undergone alloHSCT before enrollment into the phase II
study were included in the exploratory analysis. The proportion of patients
who achieved responses (with 95% conﬁdence intervals [CIs]) are presented;
relapse-free survival and overall survival are described with Kaplan-Meier
estimates. Statistical analysis was performed using SAS version 9.3 (SAS Insti-
tute, Cary, NC).
The analysis of relapse-free survival was restricted to patients who had
CR or CRh and was calculated relative to the date of bone marrow aspiration
when CR or CRh was ﬁrst achieved. The date of detection of hematologic
relapse, extramedullary disease, or death due to any cause, whichever was
earlier, served as the event date for relapse-free survival. A patient with CR or
CRh who did not have hematologic relapse and did not die was censored on
the date of the last available bone marrow aspiration or the last survival fol-
low-up visit, whichever was later. Overall survival was calculated relative to
the start of blinatumomab treatment. Patients alive were censored on the last
documented visit date or last contact date.
RESULTS
Patients and Treatment
Sixty-four of the 189 patients enrolled and treated with bli-
natumomab in the phase II study had relapsed after previous
alloHSCT, of whom 67% were male and 63% were age <35
years (Table 1). Similar proportions of patients had either a
matched sibling (47%) or an unrelated (50%) donor (20.3%
matched, 12.5% unmatched, 3.1% cord blood, and 31% with
unavailable data). Fifty-ﬁve patients (86%) had received sal-
vage therapy after alloHSCT and before treatment with blina-
tumomab. Thirty-four patients (53%) had received a
myeloablative conditioning regimen, 10 (16%) had received a
reduced-intensity conditioning regimen, 6 (9%) had undergone
2 previous transplantations before receiving blinatumomab
and had received myeloablative and reduced-intensity condi-
tioning regimens, and 14 (22%) had received regimens that
were not speciﬁed or not available. Twelve patients (19%) were
reported to have received antithymocyte globulin (ATG) ther-
apy as part of their conditioning regimen, between 103 and
574 days before enrollment.
As of the data cutoff date (June 20, 2014), 50 patients (78%)
had discontinued the study, including 47 (73%) who had died,
1 (1.6%) who was lost to follow-up, and 2 (3.1%) who withdrew
from the study. Causes of death were disease progression in 33
patients (53%); sepsis in 5 patients (8%), including 2 with fatal
adverse events of sepsis; respiratory insufﬁciency/failure in 4
patients (6%); brain hemorrhage, gastrointestinal hemorrhage,
and grade IV GVHD in 1 patient each (1.6%): and unknown
cause in 2 patients (3.1%).
Efﬁcacy of Blinatumomab in Patients with Previous AlloHSCT
Forty-ﬁve percent of patients (29 of 64) with previous
alloHSCT achieved a CR/CRh within the ﬁrst 2 cycles of treat-
ment (Table 2). The rate of CR/CRh was 43% (54 of 125) among
patients who did not have previous alloHSCT.
Among the patients with previous alloHSCT, CR/CRh within
the ﬁrst 2 cycles was achieved by 6 of 12 patients (50%) who
received previous ATG, compared with 23 of 52 patients (44%)
who did not receive previous ATG. Among the 29 patients with
previous HSCT who achieved a CR/CRh within the ﬁrst 2 cycles,
7 underwent subsequent alloHSCT after treatment with blina-
tumomab while in remission, and 3 underwent subsequent
alloHSCT after relapse. In addition, 22 of the 29 patients who
achieved CR/CRh within the ﬁrst 2 cycles had an MRD
response, including 19 with a complete MRD response
(Table 2). MRD response rates were similar in patients who did
not undergo alloHSCT before receiving blinatumomab (Supple-
mentary Table S1).
Among the 5 patients who died of sepsis during the study, 3
did not respond to blinatumomab, 1 had an unknown response
Table 1
Demographic Data and Baseline Disease Characteristics of the Patients with
Previous AlloHSCT (N = 64)
Characteristic Value
Male sex, n (%) 43 (67)
Age, yr, median (range) 32 (1974)
Age group, n (%)
18 to <35 yr 40 (63)
35 to <65 yr 22 (34)
65 yr 2 (3)
Donor type, n (%)
Haploidentical 2 (3)
Sibling 30 (47)
Unrelated 32 (50)
Degree of matching
Matched* 13 (20)
Mismatchedy 8 (12)
Cord blood (both donors 4/6
match)
1 (2)
Unavailable 10 (16)
Previous salvage after alloHSCT,
before blinatumomab, n (%)
55 (86)
Number of previous salvage therapies before blinatumomab, n (%)
None 9 (14)
1 23 (36)
2 12 (19)
3 20 (31)
Conditioning regimens for previous alloHSCT, n (%)
Myeloablative 34 (53)
Reduced intensity 10 (16)
Myeloablative and reduced
intensityz
6 (9)
Not speciﬁed/not available 14 (22)
ATG therapy as part of conditioning
regimen, n (%)
12 (19)
History of GVHD, n (%) 19 (30)
Chronic 4 (6)
Acute 1 (2)
Not speciﬁed 14 (22)
Time from previous alloHSCT to ﬁrst
blinatumomab dose, mo, median
(range)
9.7 (3.3-40.2)
Number of previous relapsesx, n (%)
1 23 (36)
2 24 (38)
>2 17 (27)
Baseline bone marrow blast category (central laboratory), n (%)
10% to <50% 19 (30)
50% 42 (66)
Lymphocyte count,£ 109/L, mean
(SD)
7.6 (15.8)
Neutrophil count,£ 109/L, mean (SD) 2.1 (2.7)
* Matched patients: 10/10, 8 patients; 11/11, 1 patient; fully matched, 4
patients.
y Mismatched patients: 9/10, 4 patients; 8/10, 2 patients; 4/6, 1 patient; and
mismatched (not speciﬁed), 1 patient.
z Underwent 2 transplantations before receiving blinatumomab.
x Before receiving blinatumomab.
Table 2
Clinical Outcomes in the Patients with Previous AlloHSCT
Outcome Value
Hematologic response (N = 64), n (%) (95% CI)
CR/CRh in ﬁrst 2 cycles 29 (45) (33-58)
CR in ﬁrst 2 cycles 18 (28) (18-41)
CRh in ﬁrst 2 cycles 11 (17) (9-29)
Blast-free hypoplastic/aplastic bone marrow 4 (6) (2-15)
Progressive disease 12 (19) (10-31)
Failure to respond to therapy 12 (19) (10-31)
No response assessment 7 (11)
Molecular response*, n (%) (N = 29)
MRD response 22 (76)
Complete MRD response 19 (66)
MRD nonresponse 4 (14)
No MRD response assessment 3 (10)
* Based on 29 patients who had achieved CR/CRh within the ﬁrst 2 cycles.
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Among the 4 patients who died of respiratory insufﬁciency/
failure, 1 relapsed and 3 did not respond to blinatumomab. The
patient who died of brain hemorrhage had relapsed, the
patient who died of gastrointestinal hemorrhage had notresponded to blinatumomab, and the patient who had grade IV
acute GVHD underwent an on-study alloHSCT and died 6
months after completing blinatumomab treatment.
The median relapse-free survival was 7.4 months (95% CI,
5.0 to 10.1 months) in patients who achieved CR/CRh in the
ﬁrst 2 cycles, with a median duration of follow-up of 12.4
months (95% CI, 11.5 to 18.0 months) (Table S2; Figure 1A).
The median relapse-free survival was 11.4 months (95% CI, 2.3
to 24.9 months) in patients who achieved CR/CRh and had 1
previous relapse and 6.2 months (95% CI, 3.8 months to not
estimable [NE]) for patients who had at least 2 previous relap-
ses (Supplementary Table S2). The median overall survival was
8.5 months (95% CI, 4.2 to 11.2 months), with a median follow-
up of 16.6 months (95% CI, 12.4 to 23.3 months) (Supplemen-
tary Table S2; Figure 1B). Similar to relapse-free survival,
overall survival was approximately twice as long for patients
with 1 previous relapse compared with patients with at least 2
previous relapses (14.3 months [95% CI, 4.0 to 23.1 months]
versus 6.5 months [95% CI, 3.5 to 9.3 months]) (Supplementary
Table S2). The median relapse-free survival and overall survival
at 3 years was 7.4 months (95% CI, 5.0 to 10.1 months) and 8.5
months (95% CI, 4.2 to 1.2 months), respectively (median fol-
low-up: relapse-free survival, 34.9 months [95% CI, 34.4 to
35.6 months]; overall survival, 36.0 months [95% CI, 35.6 to
36.4 months]) (Supplementary Figure 1). The overall survival
rate (Kaplan-Meier estimate) was 36% (95% CI, 24% to 48%) at 1
year and 18% (95% CI, 9% to 29%) at 3 years.
Of the 19 patients with previous HSCT who achieved a CR/
CRh during the ﬁrst 2 cycles of treatment and had a complete
MRD response, the median relapse-free survival was 7.6
months (95% CI, 3.8 to 11.2 months) (n = 16) and the median
overall survival was 23.1 months (95% CI, 9.4 to 25.3 months)
(n = 10), with a median follow-up of 16.6 months (95% CI, 12.4
to 19.0 months). Of the 10 patients who achieved a CR/CRh
during the ﬁrst 2 cycles of treatment and did not have a com-
plete MRD response, the median relapse-free survival was 6.1
months (95% CI, .1 month to NE) (n = 7) and the median overall
survival was 12.7 months (95% CI, 4.0 months to NE) (n = 6),
with a median follow-up of 12.8 months (95% CI, 11.2 to 23.3
months).
Safety
All 64 patients with previous alloHSCT (100%) experienced
at least 1 adverse event during the study, with grade 3, grade
4, and serious adverse events reported in 20 (31%), 28 (44%),
Figure 1. Relapse-free survival and overall survival for patients with previous alloHSCT. (A) Relapse-free survival for patients who achieved CR/CRh. (B) Overall sur-
vival. Vertical lines represent patients who were censored.
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(12.5%) had a grade 3 neurologic events, and 2 patients (3%)
had grade 3 cytokine release syndrome. Two patients had a
grade 4 neurologic event, and there were no grade 4 events of
cytokine release syndrome. The 3 most common grade 3
adverse events were neutropenia, febrile neutropenia, and
anemia. Eight patients had fatal adverse events, including 5
due to infections (2 from sepsis, 1 with Fusarium infection, 1
with bacteremia, and 1 with Candida infection considered
related to blinatumomab treatment); none of these patients
had achieved CR/CRh while receiving blinatumomab. There
were no fatal neurologic or cytokine release events.
In general, the incidences of adverse events were similar
among patients with and without previous alloHSCT. A notable
exception was the incidence of grade 4 adverse events, which
was 2-fold higher in patients who had undergone previous-
alloHSCT (Table 3).
Seven patients (11%) experienced GVHD during the study
(Table 4), including 6 after receiving blinatumomab and 1 after
undergoing subsequent on-study alloHSCT. One patient had
GVHD of the mouth (grade 1, chronic), 1 had GVHD of the skin
(grade 2 chronic); 2 had cutaneous GVHD (one grade I and one
grade III, both acute), 1 had GVHD events involving joints
(grade 2 acute arthralgia) and liver (grade 3), 1 had grade II
acute unspeciﬁed GVHD, and 1 had grade II acute GVHD of the
oral mucosa. There were no grade 4 or 5 GVHD events. None ofthe GVHD events was considered serious, none resulted in the
discontinuation of blinatumomab, and none resulted in hospi-
talization. All patients were treated with steroids, and 1 patient
also received tacrolimus (Table 4).
Seventeen of 19 patients with a history of GVHD before
treatment with blinatumomab did not develop reactivation of
GVHD following treatment with blinatumomab; only 2
patients with a history of GVHD developed GVHD during the
study.T Cell Populations at Screening
Blood samples for the determination of T cell numbers were
available for 61 patients (95%) in the previous alloHSCT group
and for 114 patients (91%) in the no previous alloHSCT group.
The distribution of CD4+ and CD8+ cell subsets measured at
screening was similar in the 2 groups of patients, although
there was an apparent trend toward higher numbers of TEM
and TEMRA cells in the previous alloHSCT group (Figure 2).DISCUSSION
The results from this exploratory analysis demonstrate that
blinatumomab is effective in patients with R/R Ph-negative B
cell precursor ALL who had relapsed following alloHSCT, a
patient population with historically poor outcomes. Of note,
65% of the patients in our study had 2 or more previous
Table 3
Adverse Events
Adverse Events* Patients with Previous AlloHSCT (N = 64), n (%) Patients without Previous AlloHSCT (N = 125), n (%)
All events, any grade 64 (100.0) 124 (99.2)
Grade 3 20 (31.3) 52 (41.6)
Neurologic events 8 (12.5) 14 (11.2)
Cytokine release syndrome 2 (3.1) 1 (.8)
Infections 14 (21.9) 26 (20.8)
Grade 4 28 (43.8) 27 (21.6)
Neurologic events 2 (3.1) 1 (.8)
Cytokine release syndrome 0 (.0) 0 (.0)
Infections 6 (9.4) 6 (4.8)
Serious 45 (70.3) 78 (62.4)
Fatal 8 (12.5) 20 (16.0)
Sepsis 1 (1.6) 3 (2.4)
Disease progression 1 (1.6) 1 (.8)
Fusarium infection 1 (1.6) 1 (.8)
Septic shock 1 (1.6) 1 (.8)
Candida infectiony 1 (1.6) 0 (.0)
Enterococcal bacteremia 1 (1.6) 0 (.0)
Gastrointestinal hemorrhage 1 (1.6) 0 (.0)
Respiratory failure 1 (1.6) 0 (.0)
Grade 3 adverse events occurring in 5 patients
Febrile neutropenia 13 (20.3) 36 (28.8)
Neutropenia 14 (21.9) 16 (12.8)
Anemia 11 (17.2) 16 (12.8)
Pneumonia 6 (9.4) 11 (8.8)
Thrombocytopenia 9 (14.1) 7 (5.6)
Leukopenia 6 (9.4) 9 (7.2)
Elevated alanine aminotransferase 8 (12.5) 6 (4.8)
Pyrexia 7 (10.9) 7 (5.6)
Hypokalemia 6 (9.4) 7 (5.6)
Decreased white blood cell count 5 (7.8) 4 (3.2)
Elevated aspartate aminotransferase 5 (7.8) 3 (2.4)
Elevated serum bilirubin 5 (7.8) 3 (2.4)
Encephalopathy 5 (7.8) 1 (.8)
Hypotension 5 (7.8) 1 (.8)
Adverse events were graded using Common Terminology Criteria for Adverse Events, version 4.0.
* During treatment until 30 days after treatment or before alloHSCT if applicable.
y Considered by the investigator to be related to blinatumomab treatment.
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of care therapy [2,3].
Among the total patient population of the phase II study,
43% of patients achieved a CR/CRh within the ﬁrst 2 cycles of
treatment, the median relapse-free survival was 5.9 months,Table 4
Patients with GVHD Events*
Patient History of GVHD GVHD Event Worst Grade Chronic/Acute
1 No Mouth 1 Chronic
2 No Skin 2 Chronic
3 Yes Cutaneous 3 Acute
4 No Cutaneous 1 Acute
5y Yes Arthralgia 2 Acute
Liver 3 Acute
6 No Not speciﬁed 2 Acute
7 No Oral mucosa 2 Chronic
* During treatment until 30 days after treatment; graded using Common Terminolo
y This patient had 2 different GVHD events.
z GVHD occurred after treatment with blinatumomab ended, within 30 days of theand the median overall survival was 6.1 months [9]. The out-
comes of patients who underwent previous alloHSCT were
similar; 45% achieved a CR/CRh within the ﬁrst 2 cycles, the
median relapse-free survival was 7.4 months, and the median
overall survival was 8.5 months. The survival rates of 36% at 1Medication for GVHD Continuation of Blinatumomab
Budesonide Yes
Not reported Yes
Dexamethasone Yes
Dexamethasone Yes
Dexamethasone Methylprednisolone,
tacrolimus
Not applicablez
Dexamethasone Yes
Methotrexate Yes
gy Criteria for Adverse Events, version 4.0.
last dose.
Figure 2. T cell subsets at baseline in patients with and without previous alloHSCT. The numbers of CD4+ and CD8+ T cells were determined by ﬂow cytometry.
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a second alloHSCT [3]. Patients who experienced more than 1
relapse after their previous alloHSCT and before treatment
with blinatumomab had shorter relapse-free survival and
overall survival compared with those with only 1 relapse. A
decreasing survival rate after subsequent lines of salvage ther-
apy has previously been reported in patients with relapsed ALL
[10].
Similar proportions of patients in the previous alloHSCT
and no previous alloHSCT groups had a complete MRD
response (66% versus 62%), providing additional evidence that
blinatumomab is effective in patients with more aggressive
ALL. As expected, patients who had an MRD response had lon-
ger relapse-free survival and overall survival compared with
patients who did not have an MRD response.
Our results are comparable to the ﬁndings in a blinatumo-
mab arm of a phase III study that compared the efﬁcacy and
safety of blinatumomab with chemotherapy. In that study, 34%
of patients had received previous alloHSCT, and the treatment
beneﬁt with blinatumomab was consistent among patients
with and patients without previous alloHSCT. Remission rates
also favored blinatumomab in both groups of patients [11].
Other novel therapeutic agents that have demonstrated efﬁ-
cacy in patients with R/R ALL include anti-CD19 chimeric
antigen receptor T cell (CAR T-cell) therapy [1214] and the
anti-CD22 antibody-calicheamicin conjugate inotuzomab ozo-
gamicin [1517]. A subgroup analysis of patients with previous
transplantation (n = 46) and without previous transplantation
(n = 29) treated with the CAR T cell agent tisagenlecleucel
showed a slightly higher rate of CR/CRh in the former group;
the CR/CRh rate was 81% for the overall patient population [12].
Other efﬁcacy outcomes were not reported for this subgroup of
patients. Two additional studies reported CR rates of 100%
(n = 8) [13] and 84% (n = 19) [14] among patients with previous
HSCT treated with CAR T cell therapy. Those studies did not
report the survival of patients with previous HSCT, however. For
the overall patient populations, 1-year survival rates were 61%
[13] and 76% [14], and after long-term follow-up, the median
overall survival among patients with low versus high disease
burden was 20.1 months versus 12.4 months [13]. In the phase
III study of inotuzomab ozogamicin versus standard of care,
patients with and without previous HSCT treated with inotuzo-
mab ozogamicin had similar CR/CRh rates (76.5% and 81.5%,respectively); relapse-free and overall survival of patients with
previous HSCT was not reported [17].
The adverse events reported in the present study were con-
sistent with those reported in previous blinatumomab clinical
studies and were generally balanced between the previous
alloHSCT and no previous alloHSCT groups. An exception was
the incidence of grade 4 adverse events, which was 2-fold
higher in the previous-alloHSCT group, a heavily pretreated
population of patients. Fatal adverse events were due mainly
to infections and occurred in patients with uncontrolled leuke-
mia. Apart from relapse, there were no other neoplastic causes
of death, and no cases of post-transplantation lymphoprolifer-
ative disease occurred after blinatumomab therapy and during
follow-up. The incidence of grade 3 neurologic events was
similar in the 2 groups. Neurologic events of grade 3 were
managed by treatment interruption or discontinuation, which
did not appear to substantially impact the response to blinatu-
momab [9]. The low incidence of grade 3 cytokine release
syndrome was likely due to premedication with dexametha-
sone and the use of a stepped-dosage regimen [9]. A low inci-
dence of cytokine release syndrome was also observed in the
phase III study using these mitigation strategies [11].
Blinatumomab treatment did not appear to be associated
with an increase in GVHD among patients with previous
alloHSCT. All but 2 cases of GVHD (which was observed in 11%
of the patients) were mild or moderate in severity; none
resulted in hospitalization, and none affected blinatumomab
treatment (ie, blinatumomab administration was not inter-
rupted). Of note, only 2 of the 7 patients who experienced
GVHD after treatment with blinatumomab had a history of
GVHD; one-third of patients who had undergone previous
alloHSCT had a history of GVHD. The incidence of GVHD in our
study cohort is lower than that observed in patients who
receive donor lymphocyte infusion for relapse after alloHSCT.
Up to 60% of patients who receive donor lymphocyte infusions
develop acute GVHD, approximately one-third develop clini-
cally signiﬁcant GVHD, and GVHD is the leading cause of mor-
tality in these patients [18,19]. Blinatumomab treatment was
not associated with any fatal cases of veno-occlusive disease,
which is considered a major toxicity in patients treated with
inotuzumab ozogamicin [1517,20]. In addition, we did not
observe any cases of Epstein-Barr virus-associated post-
transplantation lymphoproliferative disorder.
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were similar in the previous allo HSCT and no previous
alloHSCT groups, even though approximately one-third of
patients had received ATG before alloHSCT. These data reﬂect
the similar outcomes observed in both groups of patients.
Although this was not investigated in the present study, it has
been reported that a cutoff of 8.52% regulatory T cells at base-
line identiﬁed 100% of patients who will respond to blinatumo-
mab and excluded 70% of those who will not respond to
blinatumomab [21].
Our present study has some limitations. This phase II study
was not speciﬁcally designed to prospectively evaluate the
outcomes of patients who underwent previous alloHSCT,
potentially limiting the capture of transplantation data. In
addition, this retrospective analysis was performed on a small
subset of patients enrolled in a single-arm, open-label study.
In summary, blinatumomab appears to be a feasible and
effective salvage therapy for patients with R/R ALL after
alloHSCT and is not associated with a higher rate of severe side
effects compared with patients who do not undergo alloHSCT.
Several ongoing studies in patients with R/R ALL are evaluating
blinatumomab in combination with other agents, including
inotuzumab ozogamicin, the anti-PD-1 immunotherapy agents
pembrolizumab and nivolumab, and the anti-CTLA-4 immuno-
therapy agent ipilimumab. Further improvements in the out-
comes of patients with R/R ALL await the results of these
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